Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS  

Dr Garcia-Manero to Dr Oliva: What present challenges exist for treating patients with lower-risk MDS? Do not take to transplant. Challenge for other cytopenias—no drug for this. Remission of low-risk disease.

Videos

Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias. 

Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification 

Dr Garcia-Manero to Panel: How have the updates to WHO (

) and ICC guidelines impacted how you identify, diagnose, and classify myelodysplastic syndromes?

@01:40 –3:00 Dr. Thomas Cluzeau: Please comment on the newest risk stratification tool, IPSS-M. Is this something you are using in practice? What is the impact of this tool in practice?

Dr Komrokji:@3:10 higher risk what to consider does not affect the lower risk.

@4:25 - Dr Oliva: How do you distinguish between patients with pre-MDS (CHIP, CCUS, etc.) and lower-risk MDS?

The expert panel in hematologyists examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes. 

Thomas Cluzeau, MD, PhD

Articles

Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS

Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification